NovoCure
NVCR
228 hedge funds and large institutions have $1.7B invested in NovoCure in 2025 Q1 according to their latest regulatory filings, with 38 funds opening new positions, 72 increasing their positions, 76 reducing their positions, and 48 closing their positions.
692% more call options, than puts
Call options by funds: $21.2M | Put options by funds: $2.68M
1.97% more ownership
Funds ownership: 84.63% → 86.6% (+2%)
5% less repeat investments, than reductions
Existing positions increased: 72 | Existing positions reduced: 76
5% less funds holding
Funds holding: 239 → 228 (-11)
21% less first-time investments, than exits
New positions opened: 38 | Existing positions closed: 48
38% less capital invested
Capital invested by funds: $2.73B → $1.7B (-$1.03B)
60% less funds holding in top 10
Funds holding in top 10: 5 → 2 (-3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
+$63.2M |
| 2 |
Marshall Wace
London,
United Kingdom
|
+$34.9M |
| 3 |
UBS AM
Chicago,
Illinois
|
+$24.5M |
| 4 |
QCM
Quantinno Capital Management
New York
|
+$15.8M |
| 5 |
DM
Deerfield Management
New York
|
+$14.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
-$50.4M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$27.3M |
| 3 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$15.6M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$12.4M |
| 5 |
SCM
Superstring Capital Management
New York
|
-$8.55M |
NVCR Hedge Fund Activity: Q1 2025 in Review
228 of the 7,459 institutional investors tracked by Wall St. Rank reported a position in NovoCure (NVCR) for Q1 2025, worth a combined $1.7B — down 38% from $2.73B a quarter earlier.
Sellers outnumbered buyers: 48 funds closed out of NVCR and 38 opened new positions — a net loss of 10 holders — while 76 trimmed existing stakes and 72 added.
The largest buyer was Soleus Capital Management, adding an estimated $63.2M. The largest seller was T. Rowe Price Investment Management, exiting entirely with an estimated $50.4M sold.
- 228 institutional investors held NovoCure (NVCR) as of Q1 2025, down from 239 in Q4 2024.
- Funds reported $1.7B of NovoCure stock for Q1 2025, down 38% quarter-over-quarter.
- 38 funds opened new NovoCure positions in Q1 2025 and 48 closed out, a net change of -10 holders.
- The largest NovoCure buyer in Q1 2025 was Soleus Capital Management, an estimated $63.2M added.
- The largest NovoCure seller in Q1 2025 was T. Rowe Price Investment Management, an estimated $50.4M sold.
Based on aggregated 13F filings for Q1 2025.